Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

ADC Therapeutics SA (ADCT) had Revenue of $19.25M for the most recently reported fiscal quarter, ending 2026-06-30.

Quarterly Annual

Figures for fiscal quarter ending 2026-06-30

Income Statement Financials
Revenue	$19.25M
Net Income	$-16.57M
Cost of Goods Sold	$2.35M
Gross Profit	$16.90M
Operating Expenses	$44.66M
Operating Income	$-25.41M
Non-Operating Income/Expense	$8.85M
Pre-Tax Income	$-16.57M
Normalized Pre-Tax Income	$-16.57M
Income after Taxes	$-16.57M
Income from Continuous Operations	$-16.57M
Consolidated Net Income/Loss	$-16.57M
Normalized Income after Taxes	$-16.57M
EBIT	$-25.41M
EBITDA	$-25.41M
Weighted-Average Shares Outstanding (Basic)	155.02M
Weighted-Average Shares Outstanding (Diluted)	155.02M
Earnings per Share (EPS) (Basic)	$-0.11
Earnings per Share (EPS) (Diluted)	$-0.11
Balance Sheet Financials
Current Assets	$261.71M
Property, Plant, and Equipment	--
Long-Term Assets	$17.67M
Total Assets	$279.38M
Current Liabilities	$86.33M
Long-Term Debt	$110.44M
Long-Term Liabilities	$421.25M
Total Liabilities	$507.58M
Common Equity	$-228.20M
Tangible Shareholders Equity	$-228.21M
Shareholders Equity	$-228.21M
Common Shares Outstanding	127.44M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$-41.52M
Cash Flow from Investing Activities	$-0.03M
Cash Flow from Financial Activities	$-0.68M
Beginning Cash	$261.34M
End Cash	$219.11M
Increase/Decrease in Cash	$-42.23M
Stock-Based Compensation	$6.99M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	3.03
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	-0.94
Debt to Equity Ratio	-0.51
Gross Margin	87.80%
Operating Margin	-132.03%
EBIT Margin	-132.03%
EBITDA Margin	--
Pre-Tax Profit Margin	-86.06%
Profit Margin	-86.06%
Free Cash Flow	$-41.55M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.07
Inventory Turnover	0.48
Receiveable Turnover	0.69
Days Sales in Receivables	131.09
Return on Equity	7.26%
Return on Tangible Equity	7.26%
Return on Assets	-5.93%
Return on Investments	14.07%
Book Value Per Share	$-1.79
Free Cash Flow per Share	$-0.27
Operating Cash Flow per Share	$-0.27

Data from Zacks Investment Research, Inc.